1. Edelman DA, Jiang Y, Tyburski J, Wilson RF, Steffes
C. Pericytes and their role in microvasculature homeostasis. J
Surg Res. 2006;135(2):305-311.
2. Yamagishi S, Imaizumi T. Pericyte biology and diseases. Int
J Tissue React. 2005;27(3):125-135.
3. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1
by cultured endothelial cells. J Biol Chem. 1992;267(23):16066-16068.
4. Brown MJ. Renin: friend or foe? Heart. 2007;93(9):1026-1033.
5. Didion SP, Faraci FM. Effects of NADH and NADPH on superoxide
levels and cerebral vascular tone. Am J Physiol Heart Circ
Physiol. 2002;282(2):H688-H695.
6. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of
endothelium-derived relaxing factor. Am J Physiol. 1986;250(6
pt 2):H1145-H1149.
7. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts
for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524-526.
8. Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin
I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc
Natl Acad Sci U S A. 1977;74(9):3922-3926.
9. Metcalf DJ, Nightingale TD, Zenner HL, Lui-Roberts WW, Cutler
DF. Formation and function of Weibel-Palade bodies. J Cell
Sci. 2008;121(pt 1):19-27.
10. Michaux G, Abbitt KB, Collinson LM, Haberichter SL, Norman KE,
Cutler DF. The physiological function of von Willebrand’s
factor depends on its tubular storage in endothelial Weibel-Palade
bodies. Dev Cell. 2006;10(2):223-232.
11. Paulsson M. Basement membrane proteins: structure, assembly,
and cellular interactions. Crit Rev Biochem Mol Biol. 1992;27(1-2):93-127.
12. Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: structure,
gene organization, and role in human diseases: molecular basis of
Goodpasture and Alport syndromes and diffuse leiomyomatosis. J
Biol Chem. 1993;268(35):26033-26036.
13. Colognato H, Yurchenco PD. Form and function: the laminin family
of heterotrimers. Dev Dyn. 2000;218(2):213-234.
14. Vracko R. Basal lamina scaffold-anatomy and significance
for maintenance of orderly tissue structure. Am J Pathol. 1974;77(2):314-346.
15. Kleinman HK, Cannon FB, Laurie GW, et al. Biological activities
of laminin. J Cell Biochem. 1985;27(4):317-325.
16. Graf J, Iwamoto Y, Sasaki M, et al. Identification of an
amino acid sequence in laminin mediating cell attachment, chemotaxis, and
receptor binding. Cell. 1987;48(6):989-996.
17. Graf J, Ogle RC, Robey FA, et al. A pentapeptide from the
laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor. Biochemistry. 1987;26(22):6896-6900.
18. Cheng YS, Champliaud MF, Burgeson RE, Marinkovich MP, Yurchenco
PD. Self-assembly of laminin isoforms. J Biol Chem. 1997;272(50):31525-31532.
19. Moscatelli D, Jaffe E, Rifkin DB. Tetradecanoyl phorbol
acetate stimulates latent collagenase production by cultured human
endothelial cells. Cell. 1980;20(2):343-351.
20. Gross JL, Moscatelli D, Jaffe E, Rifkin DB. Plasminogen
activator and collagenase production by cultured capillary endothelial cells. J
Cell Biol. 1982;95(3):974-981.
21. Kalebic T, Garbisa S, Glaser B, Liotta LA. Basement membrane
collagen: degradation by migrating endothelial cells. Science. 1983;221(4607):281-283.
22. Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen-platelet
interactions: evidence for a direct interaction of collagen with
platelet GPIa/IIa and an indirect interaction with platelet
GPIIb/IIIa mediated by adhesive proteins. Blood. 1989;74(1):182-192.
23. Goto S, Tamura N, Handa S, Arai M, Kodama K, Takayama H. Involvement
of glycoprotein VI in platelet thrombus formation on both collagen
and von Willebrand factor surfaces under flow conditions. Circulation. 2002;106(2):266-272.
24. Massberg S, Gawaz M, Grüner S, et al. A crucial
role of glycoprotein VI for platelet recruitment to the injured
arterial wall in vivo. J Exp Med. 2003;197(1):41-49.
25. Wohner N. Role of cellular elements in thrombus formation
and dissolution. Cardiovasc Hematol Agents Med Chem. 2008;6(3):244-248.
26. Israels SJ, Rand ML, Michelson AD. Neonatal platelet function. Semin
Thromb Hemost. 2003;29(4):363-372.
27. Saxonhouse MA, Sola MC. Platelet function in term and preterm
neonates. Clin Perinatol. 2004;31(1):15-28.
28. Michelson AD. Platelet function in the newborn. Semin
Thromb Hemost. 1998;24(6):507-512.
29. Andrew M, Paes B, Johnston M. Development of the hemostatic system
in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12(1):95-104.
30. Andrew M, Paes B, Milner R, et al. Development of the human coagulation
system in the full-term infant. Blood. 1987;70(1):165-172.
31. Andrew M, Paes B, Milner R, et al. Development of the human coagulation
system in the healthy premature infant. Blood. 1988;72(5):
1651-1657.
32. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell
L. Maturation of the hemostatic system during childhood. Blood. 1992;80(8):1998-2005.
33. Andrew M, Karpatkin M. A simple screening test for evaluating
prolonged partial thromboplastin times in newborn infants. J
Pediatr. 1982;101(4):610-612.
34. Gordon EM, Ratnoff OD, Saito H, Gross S, Jones PK. Studies on
some coagulation factors (Hageman factor, plasma prekallikrein,
and high molecular weight kininogen) in the normal newborn. Am
J Pediatr Hematol Oncol. 1980;2(3):213-216.
35. Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy
J, Gruel Y. Evolution of blood coagulation activators and inhibitors
in the healthy human fetus. Blood. 1996;88(3):900-906.
36. Mazurier C, Daffos F, Forestier F. Electrophoretic and functional
characteristics of the von Willebrand factor in human fetal plasma. Br
J Haematol. 1992;81(2):263-270.
37. Schmidt B, Mitchell L, Ofosu FA, Andrew M. Alpha-2-macroglobulin
is an important progressive inhibitor of
thrombin in neonatal and
infant plasma.
Thromb Haemost. 1989;62(4):1074-1077.
38. Levine JJ, Udall JN Jr, Evernden BA, Epstein MF, Bloch KJ. Elevated
levels of alpha 2-macroglobulin-protease complexes in infants. Biol
Neonate. 1987;51(3):149-155.
39. Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin
may provide protection from thromboembolic events in antithrombin
III-deficient children. Blood. 1991;78(9):2299-2304.
40. Knöfler R, Hofmann S, Weissbach G, et al. Molecular
markers of the endothelium, the coagulation and the fibrinolytic
systems in healthy newborns. Semin Thromb Hemost. 1998;24(5):453-461.
41. Schwarz HP, Mutean W, Watzke H, Richter B, Griffin JH. Low
total protein S antigen but high protein S activity due to decreased
C4b-binding protein in neonates. Blood. 1988;71(3):562-565.
42. Weissbach G, Harenberg J, Wendisch J, Pargac N, Thomas K. Tissue
factor pathway inhibitor in infants and children.
Thromb
Res. 1994; 73(6):441-446.
[PubMed: 8073396]
43. Shah JK, Mitchell LG, Paes B, Ofosu FA, Schmidt B, Andrew
M.
Thrombin inhibition is impaired in plasma of sick neonates.
Pediatr
Res. 1992;31(4 pt 1):391-395.
44. Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F.
Thrombin
generation in newborn plasma is critically dependent on the concentration
of prothrombin.
Thromb Haemost. 1990;63(1):27-30.
45. Andrew M. Developmental hemostasis: relevance to thromboembolic
complications in pediatric patients. Thromb Haemost. 1995;74(1):415-425.
46. Andrew M. The relevance of developmental hemostasis to hemorrhagic
disorders of newborns. Semin Perinatol. 1997;21(1):70-85.
47. Sutor A. Thrombosis in the newborn and infants. In: Poller
L, Thomson J, eds. Thrombosis and Its Management. Edinburgh:
Churchill Livingstone; 1992:126-133.
48. Andrew M, Mitchell L, Vegh P, Ofosu F.
Thrombin regulation in
children differs from adults in the absence and presence of
heparin.
Thromb
Haemost. 1994;72(6):836-842.
49. Corrigan JJ Jr, Sleeth JJ, Jeter M, Lox CD. Newborn’s
fibrinolytic mechanism: components and plasmin generation. Am
J Hematol. 1989;32(4): 273-278.
50. Ginsberg JS, Hirsh J, Rainbow AJ, Coates G. Risks to the
fetus of radiologic procedures used in the diagnosis of maternal
venous thromboembolic disease. Thromb Haemost. 1989;61(2):189-196.
51. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD.
Antithrombotic therapy in children: the Seventh ACCP Conference
on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3
suppl):645S-687S.
52. Andrew M, David M, Adams M, et al. Venous thromboembolic complications
(VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251-1257.
53. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD.
Involvement of large plasma von Willebrand factor (vWF) multimers
and unusually large vWF forms derived from endothelial cells in
shear stress-induced platelet aggregation. J Clin Invest. 1986;78(6):1456-1461.
54. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake
JL. Shear-induced platelet aggregation requires von Willebrand factor
and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 1987;69(2):625-628.
55. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD.
Shear-induced platelet aggregation can be mediated by vWF released
from platelets, as well as by exogenous large or unusually large vWF
multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 1988;71(5):1366-1374.
56. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan
P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus
formation on subendothelium mediated by glycoprotein IIb-IIIa complex
at high shear rate. J Clin Invest. 1989;83(1):288-297.
57. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor
and fibrinogen in platelet aggregation under varying shear stress. J
Clin Invest. 1991;87(4):1234-1240.
58. AAssar OS, Friedman CM, White RI Jr. The natural history
of epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 1991;101
(9):977-980.
59. Haitjema T, Balder W, Disch FJ, Westerman CJ. Epistaxis
in hereditary haemorrhagic telangiectasia. Rhinology. 1996;34(3):176-178.
60. Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with
hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2000;95(2):415-418.
61. Kjeldsen AD, Oxhøj H, Andersen PE, Green A, Vase
P. Prevalence of pulmonary arteriovenous malformations (PAVMs) and
occurrence of neurological symptoms in patients with hereditary haemorrhagic
telangiectasia (HHT). J Intern Med. 2000;248(3):255-262.
62. Solomon S, Kleiman AH. Hereditary hemorrhagic telangiectasia
associated with polycystic disease of kidneys. N Y State
J Med. 1971;71 (13):1665-1668.
63. Notoya A, Bohgaki T, Mukai M, Kohno M, Sato H, Sawada K. Splenomegaly
and chronic disseminated intravascular coagulation in Osler-Weber-Rendu disease:
a case report. Am J Hematol. 2000;65(4):315-318.
64. Cos LR, Rabinowitz R, Bryson MF, Turula J, Valvo JR. Hereditary
hemorrhagic telangiectasia of bladder in a child. Urology. 1982;20(3):302-304.
65. Kitchens CS, Lottenberg R. Chronic painless hematuria and urethral
bleeding as the presenting manifestations of Osler-Weber-Rendu disease. J
Urol. 1976;116(5):681-682.
66. Larson AM. Liver disease in hereditary hemorrhagic telangiectasia. J
Clin Gastroenterol. 2003;36(2):149-158.
67. McDonald MT, Brophy BP, Kneebone C. Rendu-Osler-Weber syndrome:
a current perspective on cerebral manifestations. J Clin
Neurosci. 1998;5(3):345-350.
68. Mei-Zahav M, Letarte M, Faughnan ME, Abdalla SA, Cymerman
U, MacLusky IB. Symptomatic children with hereditary hemorrhagic
telangiectasia: a pediatric center experience. Arch Pediatr
Adolesc Med. 2006;160(6):596-601.
69. Shovlin CL, Hughes JM, Tuddenham EG, et al. A gene for hereditary
haemorrhagic telangiectasia maps to chromosome 9q3. Nat
Genet. 1994;6(2):205-209.
70. McDonald MT, Papenberg KA, Ghosh S, et al. A disease locus
for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat
Genet. 1994;6(2):197-204.
71. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta
binding protein of endothelial cells, is the gene for hereditary
haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345-351.
72. Johnson DW, Berg JN, Gallione CJ, et al. A second locus
for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome
Res. 1995;5(1):21-28.
73. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the
activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia
type 2. Nat Genet. 1996;13(2):189-195.
74. McKusick VA, Pyeritz RE. Heritable and developmental disorders
of connective tissues and bone. In: McCarty DJ, ed. Arthritis
and Allied Conditions. Philadelphia: Lea & Febiger; 1985:1168-1194.
75. Prockop DJ, Kivirikko KI. Heritable diseases of collagen. N
Engl J Med. 1984;311(6):376-386.
76. Pope FM. Ehlers-Danlos syndrome. Baillieres Clin
Rheumatol. 1991;5(2):321-349.
77. Byers PH. Ehlers-Danlos syndrome: recent advances and current
understanding of the clinical and genetic heterogeneity. J
Invest Dermatol. 1994;103(5 suppl):47S-52S.
78. Sparkman RS. Ehlers-Danlos syndrome type IV: dramatic, deceptive,
and deadly. Am J Surg. 1984;147(5):703-704.
79. Germain DP. Ehlers-Danlos syndrome type IV. Orphanet
J Rare Dis. 2007;19(2):32.
80. Germain DP, Herrera-Guzman Y. Vascular Ehlers-Danlos syndrome. Ann
Genet. 2004;47(1):1-9.
81. Pichler E, Pichler L. The neonatal coagulation system and
the vitamin K deficiency bleeding—a mini review. Wien
Med Wochenschr. 2008; 158(13-14):385-395.
82. Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation
vitamin that became omnipotent. Thromb Haemost. 2007;98(1):120-125.
83. Furie KL, Kelly PJ. Homocyst(e)ine and stroke. Semin
Neurol. 2008;26(1):24-32.
84. Strain JJ, Dowey L, Ward M, Pentieva K, McNulty H. B-vitamins,
homocysteine metabolism and CVD. Proc Nutr Soc. 2004;63(4):597-603.
85. Jain SK, McCoy B, Wise R. Vitamin E and the hypercoagulability
of neonatal blood. Clin Chim Acta. 1994;225(2):97-103.
86. Olmedo JM, Yiannias JA, Windgassen EB, Gornet MK. Scurvy:
a disease almost forgotten. Int J Dermatol. 2006;45(8):9009-913.
87. Ratanachu-Ek S, Sukswai P, Jeerathanyasakun Y, Wongtapradit
L. Scurvy in pediatric patients: a review of 28 cases. J
Med Assoc Thai. 2003;86(suppl 3):S734-S740.
88. Rajakumar K. Infantile scurvy: a historical perspective. Pediatrics. 2001;108(4):E76.
89. Clemetson CA. Barlow’s disease. Med Hypothesis. 2002;59(1):52-56.
90. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic
purpura: diagnosis and management. Pediatr Clin North Am. 2008;55(2):393-420.
91. McMillan R. The pathogenesis of chronic immune thrombocytopenic
purpura. Semin Hematol. 2007;44(4 suppl 5):S3-S11.
92. Coopmah MD, Garvey MB, Freedman J, Semple JW. Cellular immune
mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus
Med Rev. 2003;17(1):69-80.
93. Yanabu M, Suzuki M, Soga T, et al. Influences of antiplatelet autoantibodies
on platelet function in immune thrombocytopenic purpura. Eur
J Haematol. 1991;46(2):101-106.
94. Dame C. Thrombopoietin in thrombocytopenias of childhood. Semin
Thromb Hemost. 2001;37(3):215-228.
95. Ramasamy I. Inherited bleeding disorders: disorders of platelet
adhesion and aggregation. Crit Rev Oncol Hematol. 2004;49(1):1-35.
96. Nurden AT. Glanzmann thrombasthenia.
Orphanet J
Rare Dis. 2006;1:10.
[PubMed: 16722529]
97. Tullu MS, Dixit PS, Nair SB, et al. Glanzmann’s thrombasthenia. Indian
J Pediatr. 2001;68(6): 563-566.
98. White JG, Kumar A, Hogan MJ. Gray platelet syndrome in a
Somalian family. Platelets. 2006;17(8):519-527.
99. White JG, Keel S, Reyes M, Burris SM. Alpha-delta platelet
storage pool deficiency in three generations. Platelets. 2007;18(1):1-10.
100. Smith MP, Cramer EM, Savidge GF. Megakaryocytes and platelets
in alpha-granule disorders. Baillieres Clin Haematol. 1997;10(1):125-148.
101. Hurford MT, Sebastiano C. Hermansky-Pudlak syndrome: report
of a case and review of the literature. Int J Clin Exp Pathol. 2008;1(6):550-554.
102. Gunay-Aygun M, Huizing M, Gahl WA. Molecular defects that
affect platelet dense granules. Semin Thromb Hemost. 2004;30(5):537-547.
103. Larsen EC, Zinkham WH, Eggleston JC, Zitelli BJ. Kasabach-Merritt
syndrome: therapeutic considerations. Pediatrics. 1987;79(6):971-980.
104. Salles II, Feys HB, Iserbyt BF, De Meyer SF, Vanhoorelbeke
K, Deckmyn H. Inherited traits affecting platelet function.
Blood
Rev. 2008; 22(3):155-172.
[PubMed: 18180086]
105. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding
disorder caused by defective scrambling of membrane phospholipids. Biochim
Biophys Acta. 2004;1636(2-3):119-128.
106. Hassan AA, Kroll MH. Acquired disorders of platelet function. Hematology
Am Soc Hematol Educ Program. 2005;403-408.
107. Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle
CE. High incidence of valproate-induced coagulation disorders in children
receiving valproic acid: a prospective study. Blood Coagul
Fibrinolysis. 2008;19(5):375-382.
108. Handin RI. Platelets and coronary artery disease. N
Engl J Med. 1996;334(17):1126-1127.
109. Ruggeri ZM. Platelets in atherothrombosis. Nat
Med. 2002;8(11):1227-1234.
110. Schafer AI. Thrombocytosis. N Engl J Med. 2004;350(12):1211-1219.
111. Frenkel EP, Mammen EF. Sticky platelet syndrome and thrombocythemia. Hematol
Oncol Clin North Am. 2003;17(1):63-83.
112. Ruiz-Arguelles GJ, Lopez-Martinez B, Cruz-Cruz D, Esparza-Silva
L, Reyes-Aulis MB. Primary thrombophilia in Mexico III: a prospective
study of the sticky platelet syndrome. Clin Appl Thromb
Hemost. 2002;8(3):273-277.
113. Freeze HH, Aebi M. Altered glycan structures: the molecular
basis of congenital disorders of glycosylation. Curr Opin
Struct Biol. 2005;15(5):490-498.
114. Schachter H. Congenital disorders involving defective N-glycosylation
of proteins. Cell Mol Life Sci. 2001;58(8):1085-1104.
115. Jaeken J, Matthijs G. Congenital disorders of glycosylation:
a rapidly expanding disease family.
Annu Rev Genomics Hum
Genet. 2007;8:261-278.
[PubMed: 17506657]
116. Varki A. Biological roles of oligosaccharides: all of the
theories are correct. Glycobiology. 1993;3(2):
97-103.
117. Babovic-Vuksanovic D, Patterson MC, Schwenk WF, et al.
Severe hypoglycemia as a presenting symptom of carbohydrate-deficient glycoprotein
syndrome. J Pediatr. 1999;135(6):775-781.
118. de Lonlay P, Cuer M, Vuillaumier-Barrot S, et al. Hyperinsulinemic
hypoglycemia as a presenting sign in phosphomannose isomerase deficiency:
a new manifestation of carbohydrate-deficient glycoprotein syndrome
treatable with mannose. J Pediatr. 1999;135(3):379-383.
119. Niehues R, Hasilik M, Alton G, et al. Carbohydrate-deficient
glycoprotein syndrome type Ib: phosphomannose isomerase deficiency
and mannose therapy. J Clin Invest. 1998;101(7):
1414-1420.
120. Chantret I, Dancourt J, Dupré T, et al. A deficiency
in dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl alpha3-glucosyltransferase
defines a new subtype of congenital disorders of glycosylation. J
Biol Chem. 2003;278(11):9962-9971.
121. Grubenmann CE, Frank CG, Hülsmeier AJ, et al.
Deficiency of the first mannosylation step in the N-glycosylation
pathway causes congenital disorder of glycosylation type Ik. Hum
Mol Genet. 2004;13(5):535-542.
122. Kranz C, Denecke J, Lehle L, et al. Congenital disorder
of glycosylation type Ik (CDG-Ik): a defect of mannosyltransferase
I.
Am J Hum Genet. 2004; 74(3):545-551.
[PubMed: 14973782]
123. Van Geet C, Jaeken J, Freson K, et al. Congenital disorders
of glycosylation type Ia and IIa are associated with different primary
haemostatic complications. J Inherit Metab Dis. 2001;24(4):
477-492.
124. Peters V, Penzien JM, Reiter G, et al. Congenital disorder
of glycosylation IId (CDG-IId)—a new entity: clinical presentation
with Dandy-Walker malformation and myopathy. Neuropediatrics. 2002;33(1):27-32.
125. Martinex-Duncker I, Dupré T, Piller V, et al. Genetic
complementation reveals a novel human congenital disorder of glycosylation
of type II, due to inactivation of the Golgi CMP-sialic acid transporter. Blood. 2005;105(7):2671-2676.
126. Peyvandi F, Jayandharan G, Chandy M, et al. Genetic diagnosis
of haemophilia and other inherited bleeding disorders. Haemophilia. 2006;
12(suppl 3):82-89.
127. Chalmers EA. Haemophilia and the newborn. Blood
Rev. 2004;18(2):85-92.
128. Sadler JE, Budde U, Eikenboom JC, et al. Update on the
pathophysiology and classification of von Willebrand disease: a
report of the Subcommittee on von Willebrand Factor. J Thromb
Haemost. 2006;4(10):2103-2114.
129. Budde U. Diagnosis of von Willebrand disease subtypes:
implications for treatment. Haemophilia. 2008;14(suppl
5):27-38.
130. Castaman G, Federici AB, Rodeghiero F, Mannucci PM. Von
Willebrand’s disease in the year 2003: towards the complete
identification of gene defects for correct diagnosis and treatment. Haematologica. 2003;88(1):94-108.
131. Federici AB, Castaman G, Mannucci PM, Italian Association
of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of
von Willebrand disease in Italy. Haemophilia. 2002;8(5):607-621.
132. Schneppenheim R, Budde U. Phenotypic and genotypic diagnosis
of von Willebrand disease: a 2004 update. Semin Hematol. 2005;42(1):15-28.
133. Acharya SS, Coughlin A, Dimichele DM, North American Rare
Bleeding Disorder Study Group. Rare Bleeding Disorder Registry:
deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J
Thromb Haemost. 2004;2(2): 248-256.
134. Girolami A, Ruzzon E, Tezza F, Allemand E, Vettore S. Congenital
combined defects of factor VII: a critical review. Acta
Haematol. 2007;117(1):51-56.
135. Girolami A, Ruzzon E, Tezza F, Scandellari R, Scapin M,
Scarparo P. Congenital FX deficiency combined with other clotting
defects or with other abnormalities: a critical evaluation of the
literature. Haemophilia. 2008;14(2):323-328.
136. O’Connell NM. Factor XI deficiency. Semin
Hematol. 2004;41(1 suppl 1):76-81.
137. Salomon O, Zivelin A, Livnat T, Seligsohn U. Inhibitors
to factor XI in patients with severe factor XI deficiency. Semin
Hematol. 2006;43(1 suppl 1):S10-S12.
138. Duga S, Asselta R, Tenchini ML. Coagulation factor V. Int
J Biochem Cell Biol. 2004;36(8):1393-1399.
139. Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation
factor V: the hemorrhagic side. J Thromb Haemost. 2006;4(1):26-34.
140. Zhang B, Ginsburg D. Familial multiple coagulation factor
deficiencies: new biologic insight from rare genetic bleeding disorders. J
Thromb Haemost. 2004;2(9):1564-1572.
141. Nugent DJ. Prophylaxis in rare coagulation disorders—factor
XIII deficiency. Thromb Res. 2006;118(suppl 1):S23-S28.
142. Asselta R, Duga S, Tenchini ML. The molecular basis of
quantitative fibrinogen disorders. J Thromb Haemost. 2006;4(10):2115-2129.
143. Neerman-Arbez M. Molecular basis of fibrinogen deficiency. Pathophysiol
Haemost Thromb. 2006;35(1-2):187-198.
144. Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA.
Deletion of the fibrinogen [correction of fibrogen] alpha-chain
gene (FGA) causes congenital afibrogenemia. J Clin Invest. 1999;103(2):215-218.
145. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding
and thrombosis in 55 patients with inherited afibrinogenaemia. Br
J Haematol. 1999;107(1):204-206.
146. Juhan-Vague I, Alessi MC, Declerck PJ. Pathophysiology
of fibrinolysis. Baillieres Clin Haematol. 1995;8(2):329-343.
147. Stankiewicz AJ, Crowley JP, Steiner M. Increased levels
of tissue plasminogen activator with a low plasminogen activator
inhibitor-1 in a patient with postoperative bleeding. Am
J Hematol. 1991;38(3):226-229.
148. Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M.
Congenital deficiency of alpha 2-plasmin inhibitor associated with
severe hemorrhagic tendency. J Clin Invest. 1979;63(5):877-884.
149. Yoshioka A, Kamitsuji H, Takase T, et al. Congenital deficiency
of alpha 2-plasmin inhibitor in three sisters. Haemostasis. 1982;11(3):176-184.
150. Warrell RPJr, Kempin SJ, Benua RS, Reiman RE, Young CW.
Intratumoral consumption of indium-111 labeled platelets in a patient
with hemangiomatosis and intravascular coagulation (Kasabach-Merritt
syndrome). Cancer. 1983;52 (12):2256-2260.
151. Brizel HE, Raccuglia G. Giant hemangioma with thrombocytopenia:
radioisotopic demonstration of platelet sequestration. Blood. 1965;26(6):751-764.
152. Straub PW, Kessler S, Schreiber A, Frick PG. Chronic intravascular
coagulation in Kasabach-Merritt syndrome. Preferential accumulation
of fibrinogen 131 I in a giant hemangioma. Arch Intern Med. 1972;129(3):475-478.
153. Kirton A, Schechter T, Brandao L, et al. Hemorrhagic transformation
of arterial ischemic stroke in children. J Thromb Haemost. 2007;5(suppl
1):P-T-592.
154. deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous
thrombosis in children. N Engl J Med. 2001;345(6):417-423.
155. del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology
of ischemic stroke. Thromb Res. 2000;98(3):73-81.